# Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Source: https://onco.cc/trials/nct05950139/  
OnCo record `nct05950139` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.

## Summary

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC is a phase 1/2, interventional study registered as NCT05950139 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 12 participants, started 2024-05-13 and due to reach its primary completion in 2027-07. Interventions recorded: Peptide vaccine. Conditions listed: NSCLC Stage IV; ALK Fusion Protein Expression. Primary outcome: Incidence of treatment-related adverse events; Vaccine-specific immune response. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: ARCHER
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05950139
- Phase: 1/2
- Setting: Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT05950139: https://clinicaltrials.gov/study/NCT05950139

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05950139.json